Coverage
Swedish Orphan Biovitrum AB on Monday reported a 21% rise in third-quarter revenue at constant currencies, but a significant writedown on its cancer drug Vonjo pushed the company to a net loss.
Swedish Orphan Biovitrum AB raised its full-year 2025 forecast on Sunday, citing strong third-quarter sales, while also announcing a significant non-cash impairment charge related to its drug Vonjo.
Swedish Orphan Biovitrum AB on Wednesday reported a 13% rise in second-quarter revenue, driven by strong sales in its haematology drug portfolio.
Swedish Orphan Biovitrum AB will pay partner Apellis Pharmaceuticals $275 million upfront to amend a royalty agreement for the rare disease drug Aspaveli, the company said Tuesday.
Swedish Orphan Biovitrum AB has won expanded U.S. Food and Drug Administration approval for its drug Gamifant to treat a rare and life-threatening inflammatory complication associated with Still's disease.
Filings